Clinical trials: Induced Pluripotent Stem Cell (Ips Cell)
Niemann-Pick Diseases
Induced Pluripotent Stem Cells for Niemann Pick Disease
Establishment of individualized human cellular disease models based on induced pluripotent stem cells that reflect the broad heterogeneous phenotypic spectrum of Niemann Pick disease
- Trial name
- IPSNPABC (NCT03883750)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- CENTOGENE GmbH Rostock
Hirschsprung Disease
Induced Pluripotent Stem Cells for Disease Research
The aim of this study is to determine the contribution of genetic factors to the pathogenesis of diseases, including diseases such as Parkinson's disease, Hirschsprung's disease, and autism.
- Trial name
- NCT04476225
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Parkinson Disease (PD)
Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease
This study is a Phase I/II clinical study to evaluate the safety, tolerability, and efficacy of XS411 in the treatment of EOPD. The study consists of two phases: Phase I and Phase II.
- Trial name
- NCT07166757
- Testing
- human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Alpha1-antitrypsin Deficiency
Preparation of IPSC for Cell Gene Editing for the Treatment of AATD
Alpha 1-antitrypsin (AAT) deficiency is a genetic condition that leads to lung and/or liver diseases; current treatment of weekly augmentation of AAT addresses only lung diseases with moderate efficacy.
- Trial name
- NCT06892236
- Testing
- iPSC generation
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Retinoblastoma
Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma
The goal of this study is to determine if human RB1-deficient induced pluripotent stem cells (iPSCs) can produce retina, and, furthermore, can give rise to retinoblastoma in culture.
- Trial name
- NCT02193724
- Testing
- Skin Biopsy, Blood Draw
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- St. Jude Children's Research Hospital
Autism, Tuberous Sclerosis
Studies of Autistic Patients: Gene Networks and Clinical Subtypes
Background: Researchers who are studying autism spectrum disorders are interested in developing a collection of research samples from both children with autism and healthy individuals, some of whom may be related to the children…
- Trial name
- NCT01092208
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
PD - Parkinson's Disease
Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
- Trial name
- CT1-DAP001 (NCT06482268)
- Testing
- Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Neurodegenerative Disorders
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5).
- Trial name
- NCT00874783
- Where
- Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Toxicity Due to Chemotherapy, Cardiovascular Morbidity
Investigating Cardiovascular Adverse Events Related to Cancer Treatment
Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown.
- Conditions
- Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related
- Trial name
- InvestiCAT (NCT03199300)
- Testing
- Anthracyclines, Trastuzumab, Cisplatin
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Chronic Ischemic Stroke
A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke
The principal aims of the clinical investigation involve assessing the safety profile and MTD of human forebrain neural progenitor cells (hNPC01) administered at escalated doses via single-dose intracerebral injection to subjects…
- Trial name
- NCT06299033
- Testing
- hNPC01
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hopstem Biotechnology Inc.
Morquio Disease
Establishment of Human Cellular Disease Models for Morquio Disease
Establishment of human cellular disease models for Morquio disease for an individualized therapy development having the capacity to address both hepatic and neurologic forms of the disease
- Trial name
- IPSMORQUIO (NCT03872713)
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- CENTOGENE GmbH Rostock
Induced Pluripotent Stem Cells
Generation of Haploid Stem Cells From Human Germ Cells
Human cells are diploid (contain a double set of chromosomes). The diploid genome is complex and therefore limits genetic research approaches in biomedical models.
- Trial name
- NCT01454765
- Testing
- generation of stem cells
- Where
- 2 sites in Israel
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Acute Myeloid Leukemia (AML)
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
- Trial name
- iNK-r/r AML (NCT06702098)
- Testing
- iNK cells
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
Female Urinary Incontinence and Pelvic Organ Prolapse
Biomolecular Messages Associated With the Differentiation of Human Induced Pluripotent Stem Cells to Skeletal Muscle Progenitor Cells
Female urinary incontinence and pelvic organ prolapse are common diseases especially in aged women that frequently cause urogenital infection, voiding difficulty, urinary retention, pelvic pain, constipation, and coital…
- Trial name
- NCT02836145
- Testing
- Differentiation of hiPSCs to skeletal muscle progenitors
- Volunteers
- 6 people
- Sponsor
- National Taiwan University Hospital
Lateral Epicondylitis
Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus
Evaluate the safety and preliminary efficacy of human induced pluripotent stem cell-derived extracellular vesicle (iEV) injection in the treatment of lateral epicondylitis of the humerus.
- Trial name
- iEVs (NCT07111325)
- Testing
- iEV, PRP, immobilization
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai 6th People's Hospital
Inherited Arrhythmias and Valvulopathies
Molecular Mechanism Identification in Inherited Arrhythmias and Valvulopathies From Induced Pluripotent Stem Cells
The recent developments of research on iPS (induced pluripotent stem) cells lead to the establishment of mature cell lines such as cardiomyocytes or valvular interstitial cells with genetic and cellular characteristics of the…
- Trial name
- Diag-iPS (NCT01734356)
- Testing
- Skin biopsies
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Spinal Cord Injury, Safety
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
- Conditions
- Spinal Cord Injury, Safety, Clinical Trials, Efficacy
- Trial name
- NCT06976229
- Testing
- Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Atypical Hemolytic Uremic Syndrome
Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy
Hemolytic Uremic Syndrome (HUS) is a rare disease characterized by rupture of red blood cells (hemolytic anemia), low platelet count (thrombocytopenia), and thrombotic occlusion of small vessels (thrombotic microangiopathy), with…
- Trial name
- aHUS-iPSC-EC (NCT05805202)
- Testing
- Blood sampling and urine analysis
- Where
- Italy
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Age-Related Macular Degeneration
Preparation of Patient Autologous Induced Pluripotent Stem Cell-derived Retinal Cells for AMD
This project intends to collect participant somatic cells to prepare autologous induced pluripotent stem cell-derived retinal cells for future cell therapy of age-related macular degeneration patient.
- Trial name
- NCT05991986
- Testing
- somatic cell collection
- Volunteers
- 10 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Thoracic Diseases, Respiratory Tract Diseases
A Phase I Study of iPS Cell Generation From Patients With COPD
As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and…
- Conditions
- Thoracic Diseases, Respiratory Tract Diseases, Cancer of Lung, Cancer of the Lung
- Trial name
- NCT01860898
- Testing
- Skin Biopsy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mayo Clinic